Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Post-Bariatric Hypoglycemia - Market Insight, Epidemiology, and Market Forecast - 2034
... surgery, such as gastric bypass or sleeve gastrectomy. It typically occurs within a few years after surgery. Several risk factors contribute to Post-Bariatric hypoglycemia, including rapid weight loss, altered gastrointestinal anatomy, increased insulin sensitivity, hyperinsulinemia, ... Read More
-
Drug Discovery Informatics
... at a CAGR of 9.6% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.4 Billion by the end of ... Read More
-
Hemophilia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Hemophilia A Drugs, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$21.3 Billion by the end of the ... Read More
-
Hypercalcemia Treatment
... CAGR of 9.3% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$28.0 Billion by the end of the analysis period. ... Read More
-
Anti-Inflammatory Therapeutics
... CAGR of 4.3% over the analysis period 2024-2030. Anti-Inflammatory Biologics, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$67.7 Billion by the end of the analysis ... Read More
-
MRSA Drugs
... CAGR of 4.5% over the analysis period 2024-2030. Glycopeptides & Lipoglycopeptides, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$726.5 Million by the end of the ... Read More
-
Gastrointestinal Therapeutics
... CAGR of 5.1% over the analysis period 2024-2030. Crohn`s Disease Therapeutics, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion by the end of the ... Read More
-
Gastroparesis Drugs
... CAGR of 4.8% over the analysis period 2024-2030. Idiopathic Gastroparesis Drugs, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Sterility Testing
... CAGR of 10.9% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$184.9 Million by the end of the ... Read More
-
Fragment-based Drug Discovery
... at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end of ... Read More
-
Glaucoma Therapeutics
... CAGR of 3.5% over the analysis period 2024-2030. Prostaglandins Analogs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.9 Billion by the end of the analysis ... Read More
-
Glioblastoma Multiforme Treatment (GBM)
... 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Radiation Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the ... Read More
-
Ulcerative Colitis Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$5.6 Billion by the end of the ... Read More
-
Chlamydia Infection Diagnostics and Therapeutics
... Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Diagnostics, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$1.6 Billion by ... Read More
-
Pneumonia Therapeutics
... CAGR of 6.7% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$6.8 Billion by the end of the analysis period. ... Read More
-
Pruritus Therapeutics
... CAGR of 4.6% over the analysis period 2024-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
Single-Use Bioprocessing
... CAGR of 20.8% over the analysis period 2024-2030. Single-Use Media Bags & Containers, one of the segments analyzed in the report, is expected to record a 22.6% CAGR and reach US$29.9 Billion by the end ... Read More
-
Uterine Cancer Therapeutics and Diagnostics
... Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Endometrial Carcinomas, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$19.0 Billion ... Read More
-
Veterinary Autoimmune Disease Therapeutics Global Market Report 2025
... disease therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly ... Read More
-
Allergic Rhinitis - Market Insight, Epidemiology, and Market Forecast - 2034
... of Allergic rhinitis was highest in Japan among the 7MM, accounting for approximately 65 million which is further expected to increase by 2034. The emerging drug REGN5713-5714-5715 is expected to launch in EU4 and the ... Read More
-
Thin Film Drug Manufacturing
... 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Oral Thin Film, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.9 Billion by ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Osteoporosis Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$8.1 Billion by the end of the analysis period. ... Read More
-
Botulinum Toxin
... CAGR of 8.8% over the analysis period 2024-2030. Type A, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$11.0 Billion by the end of the analysis ... Read More
Research Assistance
